BridgeBio director granted RSUs and stock options

BridgeBio Pharma director Douglas A. Dachille reported routine equity awards and existing indirect holdings.

Rhea-AI Filing Summary

BridgeBio Pharma director Douglas A. Dachille reported routine equity awards and existing indirect holdings. He received 3,990 restricted stock units (RSUs) that vest in full on June 22, 2027, contingent on his continued service on the board. Each RSU represents one share of common stock, giving him 10,579 shares of common stock held directly after the award.

He also received a stock option for 5,277 shares of common stock with a $68.92 per-share exercise price, vesting in full on June 22, 2027, also tied to continued board service. Separately, 20,000 shares of common stock are held indirectly by The Dachille 2012-1 Family Trust for his children, with his spouse as trustee. Dachille disclaims beneficial ownership of those trust shares for Section 16 and other purposes.

Insider Trade Summary

Grant/Award: 9,267 shares

Grant/Award 3 txns

Insider Dachille Douglas A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,277	$0.00	$0.00
Grant/Award	Common Stock	3,990	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,277 contracts (Direct); Common Stock — 10,579 shares (Direct); Common Stock — 20,000 shares (Indirect, By The Dachille 2012-1 Family Trust)

Footnotes (4)

1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the Reporting Person's children, for which the Reporting Person's spouse is the trustee. The Reporting Person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
4. F4. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Key Figures

RSU grant: 3,990 RSUs Stock option size: 5,277 options Option exercise price: $68.92 per share +3 more

6 metrics

RSU grant 3,990 RSUs Granted June 22, 2026; vest June 22, 2027

Stock option size 5,277 options Granted June 22, 2026; vest June 22, 2027

Option exercise price $68.92 per share Stock option for 5,277 shares

Option expiration June 21, 2036 Expiration date of 5,277-share option

Direct common shares 10,579 shares Common stock held directly after RSU grant

Indirect trust shares 20,000 shares Held by The Dachille 2012-1 Family Trust

Key Terms

restricted stock units, RSUs, Stock Option (Right to Buy), Section 16 beneficial ownership, +1 more

5 terms

restricted stock units financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

Section 16 beneficial ownership regulatory

"The Reporting Person disclaims Section 16 beneficial ownership of these securities"

2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BBIO director Douglas Dachille report on this Form 4?

Douglas Dachille reported equity awards, not open-market trades. He received 3,990 restricted stock units and a stock option for 5,277 shares, both granted at no cash cost and subject to future vesting conditions tied to continued board service.

How many BridgeBio Pharma (BBIO) RSUs were granted to Douglas Dachille?

Douglas Dachille received 3,990 restricted stock units from BridgeBio Pharma. These RSUs vest in full on June 22, 2027, if he continues serving on the company’s board, and each RSU converts into one share of BridgeBio common stock upon vesting.

What are the terms of the BBIO stock options granted to Douglas Dachille?

Dachille was granted stock options for 5,277 shares of BridgeBio common stock at a $68.92 exercise price. The options vest in full on June 22, 2027, contingent on continued board service, and expire on June 21, 2036 if not exercised earlier.

How many BridgeBio (BBIO) shares does Douglas Dachille hold directly after these awards?

After the RSU grant, Dachille holds 10,579 shares of BridgeBio common stock directly. These direct holdings reflect his personal position, separate from any shares held through family trusts or other entities disclosed in the same Form 4 filing.

What is The Dachille 2012-1 Family Trust’s position in BridgeBio Pharma (BBIO)?

The Dachille 2012-1 Family Trust holds 20,000 BridgeBio common shares for Douglas Dachille’s children. His spouse is trustee, and Dachille disclaims Section 16 beneficial ownership of these securities, meaning they are attributed to the trust rather than to him personally.

Are Douglas Dachille’s BBIO equity awards tied to any service conditions?

Yes. Both the 3,990 RSUs and the 5,277-share stock option vest in full on June 22, 2027, only if Dachille continues serving on BridgeBio’s board of directors through that date. If service ends earlier, unvested awards may be forfeited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dachille Douglas A.

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		A(1)		3,990	A	$0(2)	10,579	D
Common Stock								20,000	I	By The Dachille 2012-1 Family Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$68.92	06/22/2026		A		5,277		(4)	06/21/2036	Common Stock	5,277	$0	5,277	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the Reporting Person's children, for which the Reporting Person's spouse is the trustee. The Reporting Person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.

4. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Will Solis, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)